2020
DOI: 10.6061/clinics/2020/e2033
|View full text |Cite
|
Sign up to set email alerts
|

Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 6 publications
(4 reference statements)
0
7
0
1
Order By: Relevance
“…The administration of granulocytecolony stimulating factor (G-CSF), a treatment option for neutropenia, in patients with COVID-19 has been hypothesized to have potentially devastating results because it induces the activation of strong inflammatory pathways. 37 However, no definitive conclusions could be made owing to the limited availability of clinical evidence, and decisions should be individualized, taking risk-benefit ratio into account. Two published case reports reported different management strategies for neutropenic patients with lung cancer and COVID-19.…”
Section: Patient Characteristicsmentioning
confidence: 99%
“…The administration of granulocytecolony stimulating factor (G-CSF), a treatment option for neutropenia, in patients with COVID-19 has been hypothesized to have potentially devastating results because it induces the activation of strong inflammatory pathways. 37 However, no definitive conclusions could be made owing to the limited availability of clinical evidence, and decisions should be individualized, taking risk-benefit ratio into account. Two published case reports reported different management strategies for neutropenic patients with lung cancer and COVID-19.…”
Section: Patient Characteristicsmentioning
confidence: 99%
“…COVID-19 infection in a patient with acute myeloid leukemia is difficult to manage with dual-sided effects of granulocyte colony-stimulating factor. Granulocyte colony-stimulating factors can pronounce the neutrophilia in pneumonia, but it can also treat the lymphocytopenia of COVID-19 which is a marker of COVID’s severity [ 6 ]. Granulocyte colony-stimulating factor shortens the transit time for producing granulocytes from the bone marrow and also increases antigen-presenting cells.…”
Section: Discussionmentioning
confidence: 99%
“…We attribute this finding to the high preventive measures in our country, as well as to the extra care taken by cancer patients with regard to self-hygiene. In addition, we used granulocyte colony-stimulating factor with high-risk regimens, since there is no clear recommendation about the routine use for all cancer patients [ 16 ].…”
Section: Discussionmentioning
confidence: 99%